EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders

Maria de Fátima Dos Santos Sampaio iD, Yara Bezerra de Paiva, Tuane Bazanella Sampaio, Messias Gonzaga Pereira, Norberto Cysne Coimbra iD

Basic & Clinical Pharmacology & Toxicology · 2024

DOI: 10.1111/bcpt.13997 ↗

At a glance

Übersichtsarbeit in Basic & Clinical Pharmacology & Toxicology, 2024. Written by Maria de Fátima Dos Santos Sampaio and 4 co-authors. Institution: Laboratory of Neuroanatomy and Neuropsychobiology, Department of Pharmacology, Ribeirão Preto Medical School of the University of São Paulo (FMRP-USP…. Major MEDLINE topics: Cannabidiol, Parkinson Disease, Multiple Sclerosis, Cannabinoids. Cited 24 times so far (Crossref); 247 references. Funded by: Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Universidade de São Paulo.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Studies have demonstrated the neuroprotective effect of cannabidiol (CBD) and other Cannabis sativa L. derivatives on diseases of the central nervous system caused by their direct or indirect interaction with endocannabinoid system‐related receptors and other molecular targets, such as the 5‐HT 1A receptor, which is a potential pharmacological target of CBD. Interestingly, CBD binding with the 5‐HT 1A receptor may be suitable for the treatment of epilepsies, parkinsonian syndromes and amyotrophic lateral sclerosis, in which the 5‐HT 1A serotonergic receptor plays a key role. The aim of this review was to provide an overview of cannabinoid effects on neurological disorders, such as epilepsy, multiple sclerosis and Parkinson's diseases, and discuss their possible mechanism of action, highlighting interactions with molecular targets and the potential neuroprotective effects of phytocannabinoids. CBD has been shown to have significant therapeutic effects on epilepsy and Parkinson's disease, while nabiximols contribute to a reduction in spasticity and are a frequent option for the treatment of multiple sclerosis. Although there are multiple theories on the therapeutic potential of cannabinoids for neurological disorders, substantially greater progress in the search for strong scientific evidence of their pharmacological effectiveness is needed.

Subjects

MeSH terms (MEDLINE)

CannabidiolParkinson DiseaseMultiple SclerosisCannabinoidsEpilepsyMental DisordersHumansReceptor, Serotonin, 5-HT1AComorbidity

Author keywords

Parkinson's diseasecannabinoidsepilepsymultiple sclerosisneurological diseases and psychiatric disorders comorbidity

Substances

CannabidiolReceptor, Serotonin, 5-HT1ACannabinoids

Authors and institutions

  • Laboratory of Neuroanatomy and Neuropsychobiology, Department of Pharmacology, Ribeirão Preto Medical School of the University of São Paulo (FMRP-USP), São Paulo, Brazil.
  • Center for Agropastoralism Sciences and Technology (CCTA), North Fluminense State University (UENF), Rio de Janeiro, Brazil.
  • Psychobiology Division, Behavioural Neurosciences Institute (INeC), Ribeirão Preto, São Paulo, Brazil.
  • NAP-USP-Neurobiology of Emotions Research Center (NuPNE), Ribeirão Preto School of Medicine of the University of São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, Brazil.
  • Pharmacology Post-Graduation Program, Health Sciences Centre, Santa Maria Federal University, Santa Maria, Brazil.

ORCID profiles: Maria de Fátima Dos Santos Sampaio, Norberto Cysne Coimbra

Funding

  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Universidade de São Paulo
  • Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
  • CNPq

Cite

APA

de Fátima Dos Santos Sampaio, M., de Paiva, Y. B., Sampaio, T. B., Pereira, M. G., & Coimbra, N. C. (2024). Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13997

Vancouver

de Fátima Dos Santos Sampaio M, de Paiva YB, Sampaio TB, Pereira MG, Coimbra NC. Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.13997

BibTeX
@article{deFtimaDosSantosSampaio2024,
  author = {de Fátima Dos Santos Sampaio, Maria and de Paiva, Yara Bezerra and Sampaio, Tuane Bazanella and Pereira, Messias Gonzaga and Coimbra, Norberto Cysne},
  title = {Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2024},
  doi = {10.1111/bcpt.13997}
}
Start for free →